UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 25

Sortiert nach

A Phase II Trial of Vorinostat (Suberoylanilide Hydroxamic Acid) in Metastatic Breast Cancer: A California Cancer Consortium Study

Clinical cancer research, 2008-11, Vol.14 (21), p.7138-7142

2008

Volltextzugriff (PDF)

A Phase II Trial of Older Adults With Metastatic Breast Cancer Receiving nab-Paclitaxel: Melding the Fields of Geriatrics and Oncology

Clinical breast cancer, 2019-04, Vol.19 (2), p.89-96

2019

Volltextzugriff (PDF)

Phase I/IB trial of eribulin and everolimus in patients with triple-negative metastatic breast cancer

Journal of clinical oncology, 2014-05, Vol.32 (15_suppl), p.TPS2637-TPS2637

2014

Volltextzugriff (PDF)

Genomic profiling of metaplastic breast cancer: A single center experience

Journal of clinical oncology, 2017-05, Vol.35 (15_suppl), p.e12041-e12041

2017

Volltextzugriff (PDF)

Pilot study of secondary causes of osteoporosis/osteopenia in adults with breast cancer

Journal of clinical oncology, 2014-05, Vol.32 (15_suppl), p.e20587-e20587

2014

Volltextzugriff (PDF)

A phase II trial of older adults with metastatic breast cancer (MBC) receiving nab-paclitaxel: Melding the fields of geriatrics and oncology

Journal of clinical oncology, 2017-05, Vol.35 (15_suppl), p.10035-10035

2017

Volltextzugriff (PDF)

Effect of eribulin on cell growth and PI3K pathway activity with and without RAD001 in triple-negative and HER2-expressing breast cancer

Journal of clinical oncology, 2013-09, Vol.31 (26_suppl), p.173-173

2013

Volltextzugriff (PDF)

Association of baseline pro-inflammatory (IL-6, CRP) and coagulation (D-dimer) markers with relative dose intensity (RDI) in women with breast cancer (BC) undergoing (neo) adjuvant chemotherapy (chemo)

Journal of clinical oncology, 2015-05, Vol.33 (15_suppl), p.9539-9539

2015

Volltextzugriff (PDF)

Phi-53: (NCI#7251): Phase I trial of belinostat (PXD101) in combination with 13-cis-retinoic acid (13c-RA) in advanced solid tumor malignancies—A California Cancer Consortium NCI/CTEP sponsored trial

Journal of clinical oncology, 2013-05, Vol.31 (15_suppl), p.2526-2526

2013

Volltextzugriff (PDF)

Phase I trial of ixabepilone and vorinostat in metastatic breast cancer

Journal of clinical oncology, 2012-05, Vol.30 (15_suppl), p.1070-1070

2012

Volltextzugriff (PDF)

Phase II trial of single agent PARP inhibitor ABT-888 (veliparib [vel]) followed by postprogression therapy of vel with carboplatin (carb) in patients (pts) with stage BRCA-associated metastatic breast cancer (MBC): California Cancer Consortium trial PHII-96

Journal of clinical oncology, 2014-05, Vol.32 (15_suppl), p.1021-1021

2014

Volltextzugriff (PDF)

Pathologic complete response rates observed in women with locally advanced and inflammatory breast cancer receiving neoadjuvant carboplatin and paclitaxel

Journal of clinical oncology, 2012-05, Vol.30 (15_suppl), p.1035-1035

2012

Volltextzugriff (PDF)

Efficacy of the combination of ABT-888 (veliparib) and carboplatin in patients with BRCA-associated breast cancer

Journal of clinical oncology, 2013-05, Vol.31 (15_suppl), p.1024-1024

2013

Volltextzugriff (PDF)

ABT-888 (veliparib) in combination with carboplatin in patients with stage IV BRCA-associated breast cancer. A California Cancer Consortium Trial

Journal of clinical oncology, 2012-05, Vol.30 (15_suppl), p.1010-1010

2012

Volltextzugriff (PDF)

Phase I trials of PS-341 (bortezomib, B) in combination with topotecan (T) in advanced solid tumors: A potential pharmacokinetic (PK) interaction

Journal of clinical oncology, 2012-05, Vol.30 (15_suppl), p.3108-3108

2012

Volltextzugriff (PDF)

Mutation and immune profiling of metaplastic breast cancer: Correlation with survival

PloS one, 2019-11, Vol.14 (11), p.e0224726

2019

Volltextzugriff (PDF)

Phase I clinical trial of the combination of eribulin and everolimus in patients with metastatic triple-negative breast cancer

Breast cancer research : BCR, 2019-11, Vol.21 (1), p.119-13, Article 119

2019

Volltextzugriff (PDF)

Eribulin Synergistically Increases Anti-Tumor Activity of an mTOR Inhibitor by Inhibiting pAKT/pS6K/pS6 in Triple Negative Breast Cancer

Cells (Basel, Switzerland), 2019-08, Vol.8 (9), p.1010

2019

Volltextzugriff (PDF)

Phase IB trial of ixabepilone and vorinostat in metastatic breast cancer

Breast cancer research and treatment, 2018, Vol.167 (2), p.469-478

2018

Volltextzugriff (PDF)

Phase I trial of belinostat in combination with 13-cis-retinoic acid in advanced solid tumor malignancies: a California Cancer Consortium NCI/CTEP sponsored trial

Cancer chemotherapy and pharmacology, 2019-12, Vol.84 (6), p.1201-1208

2019

Volltextzugriff (PDF)

The Effect of Aromatase Inhibition on the Cognitive Function of Older Patients With Breast Cancer

Clinical breast cancer, 2014-04, Vol.14 (2), p.132-140

2014

Volltextzugriff (PDF)

Pathologic complete response rates in triple-negative, HER2-positive, and hormone receptor-positive breast cancers after anthracycline-free neoadjuvant chemotherapy with carboplatin and paclitaxel with or without trastuzumab

Breast (Edinburgh), 2015-02, Vol.24 (1), p.18-23

2015

Volltextzugriff (PDF)

A phase II study of cell cycle inhibitor UCN-01 in patients with metastatic melanoma: a California Cancer Consortium trial

Investigational new drugs, 2012-04, Vol.30 (2), p.741-748

2012

Volltextzugriff (PDF)

Phase I Trial of Fixed-Dose Rate Gemcitabine in Combination with Bortezomib in Advanced Solid Tumors

Anticancer research, 2010-01, Vol.30 (1), p.167-174

2010

Volltextzugriff (PDF)

1 – 25 von 25

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(25)
Mit Volltextzugriff
(25)

Publikationsform

Artikel
(25)

Sprache

Englisch
(25)
Japanisch
(2)

Erscheinungsjahr

n.n

Thema

Science & Technology
(11)
Humans
(10)
Life Sciences & Biomedicine
(10)
Oncology
(10)
Aged
(9)
Female
(9)
Adult
(7)
Aged, 80 And Over
(7)
Middle Aged
(7)
Tumors
(6)
Breast Cancer
(5)
Breast Neoplasms - Drug Therapy
(5)
Drug Administration Schedule
(5)
Breast Neoplasms - Pathology
(4)
Antineoplastic Combined Chemotherapy Protocols - Therapeutic Use
(3)
Cancer Research
(3)
Cancer Therapies
(3)
Chemotherapy
(3)
Clinical Trials
(3)
Disease-Free Survival
(3)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

A Phase II Trial of Vorinostat (Suberoylanilide Hydroxamic Acid) in Metastatic Breast Cancer: A California Cancer Consortium Study

A Phase II Trial of Older Adults With Metastatic Breast Cancer Receiving nab-Paclitaxel: Melding the Fields of Geriatrics and Oncology

Phase I/IB trial of eribulin and everolimus in patients with triple-negative metastatic breast cancer

Genomic profiling of metaplastic breast cancer: A single center experience

Pilot study of secondary causes of osteoporosis/osteopenia in adults with breast cancer

A phase II trial of older adults with metastatic breast cancer (MBC) receiving nab-paclitaxel: Melding the fields of geriatrics and oncology

Effect of eribulin on cell growth and PI3K pathway activity with and without RAD001 in triple-negative and HER2-expressing breast cancer

Association of baseline pro-inflammatory (IL-6, CRP) and coagulation (D-dimer) markers with relative dose intensity (RDI) in women with breast cancer (BC) undergoing (neo) adjuvant chemotherapy (chemo)

Phi-53: (NCI#7251): Phase I trial of belinostat (PXD101) in combination with 13-cis-retinoic acid (13c-RA) in advanced solid tumor malignancies—A California Cancer Consortium NCI/CTEP sponsored trial

Efficacy of the PARP inhibitor (PI) ABT-888 (veliparib [vel]) either with carboplatin (carb) or as a single agent followed by post-progression therapy in combination with carb in patients (pts) with BRCA1 - or BRCA2 - ( BRCA )-associated metastatic breast cancer (MBC)

Phase I trial of ixabepilone and vorinostat in metastatic breast cancer

Phase II trial of single agent PARP inhibitor ABT-888 (veliparib [vel]) followed by postprogression therapy of vel with carboplatin (carb) in patients (pts) with stage BRCA-associated metastatic breast cancer (MBC): California Cancer Consortium trial PHII-96

Pathologic complete response rates observed in women with locally advanced and inflammatory breast cancer receiving neoadjuvant carboplatin and paclitaxel

Efficacy of the combination of ABT-888 (veliparib) and carboplatin in patients with BRCA-associated breast cancer

ABT-888 (veliparib) in combination with carboplatin in patients with stage IV BRCA-associated breast cancer. A California Cancer Consortium Trial

Phase I trials of PS-341 (bortezomib, B) in combination with topotecan (T) in advanced solid tumors: A potential pharmacokinetic (PK) interaction

Mutation and immune profiling of metaplastic breast cancer: Correlation with survival

Phase I clinical trial of the combination of eribulin and everolimus in patients with metastatic triple-negative breast cancer

Eribulin Synergistically Increases Anti-Tumor Activity of an mTOR Inhibitor by Inhibiting pAKT/pS6K/pS6 in Triple Negative Breast Cancer

Phase IB trial of ixabepilone and vorinostat in metastatic breast cancer

Phase I trial of belinostat in combination with 13-cis-retinoic acid in advanced solid tumor malignancies: a California Cancer Consortium NCI/CTEP sponsored trial

The Effect of Aromatase Inhibition on the Cognitive Function of Older Patients With Breast Cancer

Pathologic complete response rates in triple-negative, HER2-positive, and hormone receptor-positive breast cancers after anthracycline-free neoadjuvant chemotherapy with carboplatin and paclitaxel with or without trastuzumab

A phase II study of cell cycle inhibitor UCN-01 in patients with metastatic melanoma: a California Cancer Consortium trial

Phase I Trial of Fixed-Dose Rate Gemcitabine in Combination with Bortezomib in Advanced Solid Tumors

Suchergebnisse filtern